AbbVie Inc.
ABBV- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001551152
In the last 90 days, AbbVie Inc. insiders filed 0 open-market purchases and 1 sale; 4,260 institutions reported holding it in 13F filings for Q2 2026, worth $335.4B in total; superinvestors Gardner Russo & Quinn and Harris Associates (Oakmark) hold it.
Key figures
- Market capClose on Nov 9, 2026
- $518.4B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $8.18M in total
- 1
- 13F holdersQ2 2026, +180 vs. previous quarter
- 4,260
- 13F valueReported value at the end of Q2 2026
- $335.4B
- Superinvestors holdingAt the end of Q2 2026
- 2
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $61.2B
- +8.6% year over year
- Net income, FY2025
- $4.23B
- −1.2% year over year
- Free cash flow, FY2025
- $17.8B
- −0.1% year over year
- Revenue, Q3 FY2026
- $17.4B
- +10.3% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 15.6M
- Shares sold short
- Change
- −697.8K
- −4.3% vs. previous
- Days to cover
- 2.72
- At average daily volume
Superinvestors holding ABBV, Q2 2026
Go to the superinvestors tab2 superinvestors report holding AbbVie Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Harris Associates (Oakmark)
Bill Nygren
<0.1%
AbbVie Inc.'s share of the portfolio
- Shares
- 2,420
- Value
- $609.0K
Latest insider trades
See all insider tradesOpen-market purchases and sales by AbbVie Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 (view filing)5:00 PM ET | Aug 14 | 4 days | Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER | SSaleCommon Stock, $0.01 par value | −32.7K | $250.00 | −$8.18M | −30.5%74.4K after | |
| Mar 6, 2026 (view filing) | Mar 4 | 2 days | Purdue David RyanSVP, Controller | SSaleCommon Stock, $0.01 par value | −5.23K | $233.56 | −$1.22M | −66.3%2.65K after | |
| Mar 3, 2026 (view filing) | Mar 2 | 1 day | Siatis Perry CEVP, GC AND SECRETARY | SSaleCommon Stock, $0.01 par value | −18.7K | $234.39 | −$4.38M | −80.2%4.62K after | 3 lots10b5-1 |
| Feb 27, 2026 (view filing) | Feb 25 | 2 days | Siatis Perry CEVP, GC AND SECRETARY | SSaleCommon Stock, $0.01 par value | −22.4K | $230.00 | −$5.15M | −37.0%38.1K after | 10b5-1 |
| Aug 14, 2025 (view filing) | Aug 12 | 2 days | Saleki-Gerhardt AzitaEVP, CHIEF OPERATIONS OFFICER | SSaleCommon Stock, $0.01 par value | −42.4K | $198.42 | −$8.41M | −19.3%177.3K after | |
| Aug 7, 2025 (view filing) | Aug 5 | 2 days | Donoghoe NicholasEVP, CHIEF BUS/STRAT OFFICER | SSaleCommon Stock, $0.01 par value | −13.3K | $198.51 | −$2.64M | −18.6%58.2K after | 2 lots |
| Apr 2, 2025 (view filing) | Mar 31 | 2 days | Stewart Jeffrey RyanEVP, CHIEF COMMERCIAL OFFICER | SSaleCommon Stock, $0.01 par value | −58.8K | $210.08 | −$12.4M | −52.5%53.2K after | 2 lots |
| Mar 18, 2025 (view filing) | Mar 14 | 4 days | Reents Scott TEVP, CHIEF FINANCIAL OFFICER | SSaleCommon Stock, $0.01 par value | −17.6K | $212.34 | −$3.75M | −60.4%11.6K after | |
| Mar 4, 2025 (view filing) | Mar 3 | 1 day | Richmond Timothy J.EVP, CHIEF HR OFFICER | SSaleCommon stock, $0.01 par value | −21.3K | $210.45 | −$4.47M | −77.6%6.13K after | 3 lots10b5-1 |
| Mar 4, 2025 (view filing) | Feb 28-Mar 3 | 4 days | Gonzalez Richard ADirector | SSaleCommon Stock, $0.01 par value | −98.6K | $205.45 | −$20.3M | −20.2%388.9K after | 2 lots |
Top 10 13F holders, Q2 2026
See all 4,260 holdersThe largest institutional positions in AbbVie Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 149,488,412 | $37.6B | 0.56% | −1,209,713−0.8% | Reduced |
| Vanguard Capital Management LLC | 115,396,098 | $29.0B | 0.62% | +515,774+0.4% | Added |
| State Street Corp | 82,596,748 | $20.8B | 0.61% | +1,379,232+1.7% | Added |
| Vanguard Portfolio Management LLC | 48,477,996 | $12.2B | 0.55% | −1,045,082−2.1% | Reduced |
| JPMorgan Chase & Co | 47,862,796 | $12.2B | 0.71% | −8,878,895−15.6% | Reduced |
| Geode Capital Management, LLC | 46,998,433 | $11.8B | 0.63% | +260,852+0.6% | Added |
| Morgan Stanley | 38,901,001 | $9.79B | 0.52% | +884,227+2.3% | Added |
| Capital Research Global Investors | 30,101,551 | $7.57B | 1.06% | −1,153,235−3.7% | Reduced |
| Norges Bank | 25,554,538 | $6.43B | 0.64% | +25,554,538 | New |
| Bank of America Corp | 21,237,764 | $5.34B | 0.34% | −2,699,179−11.3% | Reduced |
Holders of 5% or more of ABBV
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of AbbVie Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 13G | 7.51%132.9M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
Politician trades
All politician trades in ABBV38 members of Congress reported 119 trades in AbbVie Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Sep 18, 2026 |  Pete Sessions House · TX | Sell | $15K-$50K |
| Jul 21, 2026 |  Alan Armstrong Senate · OK | Buy | $15K-$50K |
| Jun 3, 2026 |  Josh Gottheimer House · NJ | Sell | $1K-$15K |
| Jan 15, 2026 |  Julie Johnson House · TX | Sell | $1K-$15K |
| Jan 13, 2026 |  Julia Letlow House · LA | Sell | $1K-$15K |
House · TX · Sep 18, 2026
Sell$15K-$50K
Senate · OK · Jul 21, 2026
Buy$15K-$50K
House · NJ · Jun 3, 2026
Sell$1K-$15K
House · TX · Jan 15, 2026
Sell$1K-$15K
House · LA · Jan 13, 2026
Sell$1K-$15K